Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Double-Blind, Randomised Phase 2 Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)

NCT00114764 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00114764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00114764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Double-Blind, Randomised Phase 2 Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML)
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
March 31, 2003
Completion date
August 31, 2004
Enrollment
84 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

myeloid leukemia